These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 32223236)
1. Discovery of WD Repeat-Containing Protein 5 (WDR5)-MYC Inhibitors Using Fragment-Based Methods and Structure-Based Design. Chacón Simon S; Wang F; Thomas LR; Phan J; Zhao B; Olejniczak ET; Macdonald JD; Shaw JG; Schlund C; Payne W; Creighton J; Stauffer SR; Waterson AG; Tansey WP; Fesik SW J Med Chem; 2020 Apr; 63(8):4315-4333. PubMed ID: 32223236 [TBL] [Abstract][Full Text] [Related]
2. Discovery and Optimization of Salicylic Acid-Derived Sulfonamide Inhibitors of the WD Repeat-Containing Protein 5-MYC Protein-Protein Interaction. Macdonald JD; Chacón Simon S; Han C; Wang F; Shaw JG; Howes JE; Sai J; Yuh JP; Camper D; Alicie BM; Alvarado J; Nikhar S; Payne W; Aho ER; Bauer JA; Zhao B; Phan J; Thomas LR; Rossanese OW; Tansey WP; Waterson AG; Stauffer SR; Fesik SW J Med Chem; 2019 Dec; 62(24):11232-11259. PubMed ID: 31724864 [TBL] [Abstract][Full Text] [Related]
3. Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core. Tian J; Teuscher KB; Aho ER; Alvarado JR; Mills JJ; Meyers KM; Gogliotti RD; Han C; Macdonald JD; Sai J; Shaw JG; Sensintaffar JL; Zhao B; Rietz TA; Thomas LR; Payne WG; Moore WJ; Stott GM; Kondo J; Inoue M; Coffey RJ; Tansey WP; Stauffer SR; Lee T; Fesik SW J Med Chem; 2020 Jan; 63(2):656-675. PubMed ID: 31858797 [TBL] [Abstract][Full Text] [Related]
4. Discovery and Structure-Based Design of Inhibitors of the WD Repeat-Containing Protein 5 (WDR5)-MYC Interaction. Ding J; Liu L; Chiang YL; Zhao M; Liu H; Yang F; Shen L; Lin Y; Deng H; Gao J; Sage DR; West L; Llamas LA; Hao X; Kawatkar S; Li E; Jain RK; Tallarico JA; Canham SM; Wang H J Med Chem; 2023 Jun; 66(12):8310-8323. PubMed ID: 37307526 [TBL] [Abstract][Full Text] [Related]
5. Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance. Thomas LR; Adams CM; Wang J; Weissmiller AM; Creighton J; Lorey SL; Liu Q; Fesik SW; Eischen CM; Tansey WP Proc Natl Acad Sci U S A; 2019 Dec; 116(50):25260-25268. PubMed ID: 31767764 [TBL] [Abstract][Full Text] [Related]
6. Interaction with WDR5 promotes target gene recognition and tumorigenesis by MYC. Thomas LR; Wang Q; Grieb BC; Phan J; Foshage AM; Sun Q; Olejniczak ET; Clark T; Dey S; Lorey S; Alicie B; Howard GC; Cawthon B; Ess KC; Eischen CM; Zhao Z; Fesik SW; Tansey WP Mol Cell; 2015 May; 58(3):440-52. PubMed ID: 25818646 [TBL] [Abstract][Full Text] [Related]
7. Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models. Teuscher KB; Chowdhury S; Meyers KM; Tian J; Sai J; Van Meveren M; South TM; Sensintaffar JL; Rietz TA; Goswami S; Wang J; Grieb BC; Lorey SL; Howard GC; Liu Q; Moore WJ; Stott GM; Tansey WP; Lee T; Fesik SW Proc Natl Acad Sci U S A; 2023 Jan; 120(1):e2211297120. PubMed ID: 36574664 [TBL] [Abstract][Full Text] [Related]
8. Discovery of Potent Small-Molecule Inhibitors of WDR5-MYC Interaction. Ding J; Li G; Liu H; Liu L; Lin Y; Gao J; Zhou G; Shen L; Zhao M; Yu Y; Guo W; Hommel U; Ottl J; Blank J; Aubin N; Wei Y; He H; Sage DR; Atadja PW; Li E; Jain RK; Tallarico JA; Canham SM; Chiang YL; Wang H ACS Chem Biol; 2023 Jan; 18(1):34-40. PubMed ID: 36594833 [TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders. Dölle A; Adhikari B; Krämer A; Weckesser J; Berner N; Berger LM; Diebold M; Szewczyk MM; Barsyte-Lovejoy D; Arrowsmith CH; Gebel J; Löhr F; Dötsch V; Eilers M; Heinzlmeir S; Kuster B; Sotriffer C; Wolf E; Knapp S J Med Chem; 2021 Aug; 64(15):10682-10710. PubMed ID: 33980013 [TBL] [Abstract][Full Text] [Related]
10. WDR5-Myc axis promotes the progression of glioblastoma and neuroblastoma by transcriptional activating CARM1. Wang F; Zhang J; Ke X; Peng W; Zhao G; Peng S; Xu J; Xu B; Cui H Biochem Biophys Res Commun; 2020 Mar; 523(3):699-706. PubMed ID: 31948749 [TBL] [Abstract][Full Text] [Related]
11. The MYC-WDR5 Nexus and Cancer. Thomas LR; Foshage AM; Weissmiller AM; Tansey WP Cancer Res; 2015 Oct; 75(19):4012-5. PubMed ID: 26383167 [TBL] [Abstract][Full Text] [Related]
12. WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma. Sun Y; Bell JL; Carter D; Gherardi S; Poulos RC; Milazzo G; Wong JW; Al-Awar R; Tee AE; Liu PY; Liu B; Atmadibrata B; Wong M; Trahair T; Zhao Q; Shohet JM; Haupt Y; Schulte JH; Brown PJ; Arrowsmith CH; Vedadi M; MacKenzie KL; Hüttelmaier S; Perini G; Marshall GM; Braithwaite A; Liu T Cancer Res; 2015 Dec; 75(23):5143-54. PubMed ID: 26471359 [TBL] [Abstract][Full Text] [Related]
13. Discovery, evaluation and mechanism study of WDR5-targeted small molecular inhibitors for neuroblastoma. Han QL; Zhang XL; Ren PX; Mei LH; Lin WH; Wang L; Cao Y; Li K; Bai F Acta Pharmacol Sin; 2023 Apr; 44(4):877-887. PubMed ID: 36207403 [TBL] [Abstract][Full Text] [Related]
14. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. Carabet LA; Lallous N; Leblanc E; Ban F; Morin H; Lawn S; Ghaidi F; Lee J; Mills IG; Gleave ME; Rennie PS; Cherkasov A Eur J Med Chem; 2018 Dec; 160():108-119. PubMed ID: 30326371 [TBL] [Abstract][Full Text] [Related]
15. Discovery of Potent 2-Aryl-6,7-dihydro-5 H-pyrrolo[1,2- a]imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design. Wang F; Jeon KO; Salovich JM; Macdonald JD; Alvarado J; Gogliotti RD; Phan J; Olejniczak ET; Sun Q; Wang S; Camper D; Yuh JP; Shaw JG; Sai J; Rossanese OW; Tansey WP; Stauffer SR; Fesik SW J Med Chem; 2018 Jul; 61(13):5623-5642. PubMed ID: 29889518 [TBL] [Abstract][Full Text] [Related]
16. Recent Progress in Modulation of WD40-Repeat Domain 5 Protein (WDR5): Inhibitors and Degraders. Gurung R; Om D; Pun R; Hyun S; Shin D Cancers (Basel); 2023 Aug; 15(15):. PubMed ID: 37568727 [TBL] [Abstract][Full Text] [Related]
17. Loss of Wdr5 attenuates MLL-rearranged leukemogenesis by suppressing Myc targets. Liu L; Guo X; Wang Y; Li G; Yu Y; Song Y; Zeng C; Ding Z; Qiu Y; Yan F; Zhang YX; Zhao C; Zhang Y; Dou Y; Atadja P; Li E; Wang H Biochim Biophys Acta Mol Basis Dis; 2023 Feb; 1869(2):166600. PubMed ID: 36402263 [TBL] [Abstract][Full Text] [Related]
18. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Carugo A; Genovese G; Seth S; Nezi L; Rose JL; Bossi D; Cicalese A; Shah PK; Viale A; Pettazzoni PF; Akdemir KC; Bristow CA; Robinson FS; Tepper J; Sanchez N; Gupta S; Estecio MR; Giuliani V; Dellino GI; Riva L; Yao W; Di Francesco ME; Green T; D'Alesio C; Corti D; Kang Y; Jones P; Wang H; Fleming JB; Maitra A; Pelicci PG; Chin L; DePinho RA; Lanfrancone L; Heffernan TP; Draetta GF Cell Rep; 2016 Jun; 16(1):133-147. PubMed ID: 27320920 [TBL] [Abstract][Full Text] [Related]
19. Targeting WD Repeat-Containing Protein 5 (WDR5): A Medicinal Chemistry Perspective. Chen X; Xu J; Wang X; Long G; You Q; Guo X J Med Chem; 2021 Aug; 64(15):10537-10556. PubMed ID: 34283608 [TBL] [Abstract][Full Text] [Related]
20. Cell-Based Drug Discovery: Identification and Optimization of Small Molecules that Reduce Medina JR; Tian X; Li WH; Suarez D; Mack JF; LaFrance L; Martyr C; Brackley J; Di Marco C; Rivero R; Heerding DA; McHugh C; Minthorn E; Bhaskar A; Rubin J; Butticello M; Carpenter C; Nartey EN; Berrodin TJ; Kallal LA; Mangatt B J Med Chem; 2021 Nov; 64(21):16056-16087. PubMed ID: 34669409 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]